Identification of p53 and Its Isoforms in Human Breast Carcinoma Cells by Milićević, Zorka T. et al.
Research Article
Identification of p53 and Its Isoforms in Human Breast
Carcinoma Cells
Zorka MiliTeviT,1 Vladan BajiT,2 Lada CivkoviT,3 Jelena KasapoviT,1
Uroš AndjelkoviT,4 and Biljana Spremo-PotpareviT3
1 Laboratory of Molecular Biology and Endocrinology, “Vincˇa” Institute of Nuclear Sciences, University of Belgrade,
Mihaila Petrovic´a Alasa 12-14, P.O. Box 522, 11 001 Belgrade, Serbia
2 Biomedical Department, Institute for Pharmaceutical Research and Development, Galenika a.d., Pasterova 2,
11 000 Belgrade, Serbia
3 Department of Biology and Human Genetics, Institute of Physiology, Faculty of Pharmacy, University of Belgrade,
Vojvode Stepe 450, 11 000 Belgrade, Serbia
4Department of Chemistry, Institute for Chemistry, Technology and Metallurgy, University of Belgrade,
Studentski trg 12-16, 11000 Belgrade, Serbia
Correspondence should be addressed to Jelena Kasapovic´; jelkas@vinca.rs
Received 4 September 2013; Accepted 12 November 2013; Published 5 January 2014
Academic Editors: N. L. Banik and T. Mikawa
Copyright © 2014 Zorka Milic´evic´ et al.This is an open access article distributed under the Creative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In breast carcinoma, disruption of the p53 pathway is one of the most common genetic alterations.The observation that the p53 can
express multiple protein isoforms adds a novel level of complexity to the outcome of p53 mutations. p53 expression was analysed
by Western immunoblotting and immunohistochemistry using monoclonal antibodies DO-7, Pab240, and polyclonal antiserum
CM-1. The more frequently p53-positive nuclear staining has been found in the invasive breast tumors. One of the most intriguing
findings is that mutant p53 appears as discrete dot-shaped regions within the nucleus of breast cancer cells. In many malignant
cells, the nucleolar sequestration of p53 is evident.These observations support the view that the nucleolus is involved directly in the
mediation of p53 function or indirectly by the control of the localization of p53 interplayers. p53 expressed in the nuclear fraction of
breast cancer cells revealed awide spectrumof isoforms. p53 isoformsΔNp53 (47 kDa) andΔ133p53𝛽 (35 kDa), known as dominant-
negative repressors of p53 function, were detected as themost predominant variants in nuclei of invasive breast carcinoma cells.The
isoforms expressed also varied between individual tumors, indicating potential roles of these p53 variants in human breast cancer.
1. Introduction
The tumor suppressor p53 plays a vital role in the response
to DNA damage and has been classified as a “guardian of
the genome” due to its ability to coordinate multiple and
diverse signaling pathways involved in this response [1]. Gene
expression microarrays have revealed that p53-regulated
genes are not limited to those involved in cell cycle arrest and
apoptosis. Many other gene clusters associated with diverse
processes such as DNA repair, transcription, cell adhesion,
cell mobility, metabolism, and membrane functions are also
affected by p53 activity. The complex repertoire of p53-
regulated genes further highlights the imperative need to
understand how p53 selects its key target genes. Mutation of
p53 is a common occurrence in many cancers and is asso-
ciated with tumor progression, resistance to chemotherapy,
and poor prognosis [2]. A study of breast cancers found that
p53mutation frequency was not related to nodal involvement
or tumor size [3], although another study found a marginally
increased frequency in recurrent tumors [4]. It was also
reported that inactivation of p53 may be due to inhibition
of the function of wild-type p53 itself [5]. In addition, breast
cancer patients have been found to have tumors which
are characterized by changes in the levels of wild-type p53
transcripts [6].This affects the levels of downstream products
and understanding the role of p53 in tumorigenesis would
perhaps require the characterization of mutations in proteins
that physically partner p53 and may control its levels. p53
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gene family members express multiple mRNA variants due
to multiple splicing and alternative promoters. Hence, p53
gene family members express different forms of p53 protein
containing different domain of the protein (isoforms). This
indicates that wild-type p53 activity may be modulated in
the presence of p53 isoforms. The traditional belief has been
that each p53 protein isoform may have specific biological
activities independent of full-length p53 [7–9]. While many
developments have been made in understanding the biology
of p53, this has been accompanied by an increased perception
of its complexity [10]. In the network of cancer-related genes,
pathways are the frame by which we can understand the
network logically. The goal of the molecular analysis of
human cancer is to know all genetic changes in a cancer
cell, the order in which they appear, and what the products
of these genes do. How many different possibilities there
are at the molecular level for a mammary tumor to arise
remains to be established. In the present study, marker p53
is selected based on the most frequently mutated gene, and
its expression level in breast cancer specimens was detected
by immunohistochemistry (IHC), which is generally used
for regular pathological detection. Although not every study
of p53 expression contains unequivocal information about
the pattern of expression, from the data available to date,
it would be reasonable to suggest that this would be highly
relevant in the prediction of the course of the disease.We also
compared the pattern of expression of p53 isoforms which
appear to be involved inmalignant transformation and tumor
progression. This attempt is an extension of our continued
interest in investigating the mode of action of p53 family
members and its isoforms.
2. Materials and Methods
2.1. Reagents. All reagents were purchased from Sigma (St.
Louis, MO, USA) and Merck (Darmstadt, Germany). Rabbit
anti-human p53 polyclonal antibody (CM-1) was obtained
from Midgley et al. [11]. Biotinylated swine anti-rabbit Ig
serum (E-353), mouse anti-human p53 monoclonal antibody
(clone DO-7, M-7001), biotinylated rabbit anti-mouse anti-
body (E-354), andABComplex-HRP (K-377)were purchased
from Dako Denmark (Glostrup, Denmark). Monoclonal
antibody Pab240 (sc-99), HRP-conjugated rabbit anti-mouse
IgG (sc-358917), and rabbit anti-actin antibody (C-11: 1615)
were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). HRP-conjugated goat anti-rabbit IgG (SAB-301)
were purchased from Millipore (Billerica, MA 01821, USA).
Rabbit anti-actin antibody (C-11: 1615) was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). HRP-
conjugated goat anti-rabbit IgG (SAB-301) was purchased
from Millipore (Billerica, MA 01821, USA). Human breast
carcinoma cell line (CL-239M) was purchased from Bio-
Genex (Fremont, CA, USA).
2.2. Subjects and Breast Cancer Samples. The study included
47 breast cancer patients (age in years: mean = 57, min.
= 32, and max. = 86) from the Institute of Oncology and
Radiology of Serbia, Belgrade, Serbia. All patients were newly
diagnosed and tumors were clinically categorized as stages II
and III, according to the classification of the International
Union Against Cancer [12]. Primary breast cancer cases
were classified according to TNM classification and tumors
were histologically diagnosed as ductal (30), lobular (12),
tubular (3), and medullary (2) type. Ten normal breast
tissues were selected from macroscopically normal areas
and 6 from nontumor patients. During the study period,
patients were not submitted to endocrine, chemotherapy, or
radiotherapy.The patients and the controls were nonsmokers
and they used no alcohol consumption, hormones, oral
contraceptives, or dietary supplements with antioxidants.
None of the subjects had concomitant diseases such as
diabetes mellitus, rheumatoid arthritis, liver disorders, or
any other malignancies. According to the ethical guidelines
of the Helsinki Declaration, informed consent was obtained
from all participants and the protocol used in this study was
approved by the Ethics Committee of Institute of Oncology
and Radiology of Serbia, University of Belgrade, Belgrade,
Serbia.
2.3. Tissue andCellular Fractionation. Thenormal and cancer
tissues were surgically dissected and frozen. The nuclear
fractions of normal and tumor tissues were obtained by
differential centrifugation [13]. Briefly, the samples of normal
and neoplastic tissues were minced by fine dissection and
homogenized in 0.25M sucrose, 5mM MgCl
2
, 0.5% Tri-
ton X-100, 1mM phenylmethylsulfonylfluoride (PMSF), and
50mM TRIS-HCl, pH 7.4, followed by centrifugation of the
homogenate at 800 xg for 10min (Sorvall RC-5B, Sorvall Ltd.,
Stevenage, England). The supernatants were spun at 11000 xg
at 4∘C for 25min and the resulting supernatant was again
centrifuged at 20000 xg at 4∘C for 45min (Beckman L7-55
centrifuge, Beckman Instruments Inc., Palo Alto, CA, USA).
The cytosolic fraction was obtained by further centrifugation
of supernatant at 100000 xg at 4∘C for 60min. The pellet
obtained after first centrifugation was homogenized in ice-
cold buffer (2.2M sucrose, 5mM MgCl
2
, 0.5% Triton X-100,
1mM PMSF, and 50mM Tris-HCl, pH 7.4) and further puri-
fied by centrifugation. After this step the pellets representing
the soluble nuclear proteins were resuspended in 0.25M
sucrose, 5mM MgCl
2
, 0.5% Triton X-100, 1mM PMSF, and
50mM Tris-HCl, pH 7.4. The protein concentration was
determined by Lowery et al. method [14], and samples were
aliquoted and stored at −20∘C.
2.4. SDS-Polyacrylamide Gel Electrophoresis and Immunoblot
Analysis. Proteins isolated from normal and breast cancer
cells were suspended in sample loading buffer (0.1M Tris,
pH 6.8, 20% glycerol, 4% SDS, 0.04% bromphenol blue,
10% 𝛽-mercaptoethanol) and separated electrophoretically
on 12% acrylamide gels according to procedure of Laemmli
[15]. Equal amounts of nuclear proteins (50 𝜇g) per line
were loaded and run on 12% SDS-PAGE (Mini-protean
3 Cell, Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Separated proteinswere transferred onto nitrocellulosemem-
brane (Amersham Hybond, GE Healthcare Bio-Sciences AB,
Uppsala, Sweden) according to the procedure of Towbin
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et al. [16]. Transfer of proteins from the acrylamide gel
to nitrocellulose was performed in transfer buffer (25mM
Tris, 192mM glycine, 0.1% SDS, 20% methanol, pH 7.5) at
30V, 40mA overnight at 4∘C (Trans-Blot SD Electrophoretic
Transfer Cell, Bio-Rad, Hercules, CA, USA). Nitrocellulose
filters were blocked overnight with blocking buffer (1% BSA
in 50mM Tris, 0.9% NaCl, 0.05% Tween 20, pH 7.5). The
filters were then incubated for 1 h 45min in buffer (50mM
Tris, 0.9% NaCl, 0.05% Tween 20, pH 7.5) plus primary
antibody CM-1 at the optimal dilution 1 : 1000. The CM-1
antibody is a rabbit high-titre polyclonal antiserum raised
against human recombinant wild-type p53 protein [11]. After
1 h of incubation with the biotinylated swine anti-rabbit Ig
serum (diluted 1 : 1000) and strept ABComplex-HRP conju-
gated (diluted 1 : 100) the proteins bands were visualized in a
HRP substrate diaminobenzidine tetrahydrochloride (DAB).
The same membranes were stripped and probed for 𝛽-actin
(dilution 1 : 10000) as an internal loading control. To detect
actin with rabbit polyclonal antibody, we used the HRP-
conjugated goat anti-rabbit (1 : 2000) antibodies as secondary
antibodies. Reproducibility was assessed by repeating the
protein extraction and the SDS-PAGE three times. The
protein level of each band was quantified by transmission
scanning and analyzed by Gel-Pro Analyzer 3.1.
2.5. Immunohistochemical Analysis. Immunohistochemical
(IHC) staining was performed on 3 𝜇m tissue sections by
an avidin-biotin-peroxidase complex (ABC) technique [17]
using both frozen and formalin-fixed paraffin-embedded
tissues. For formalin-fixed, paraffin-embedded sections, we
applied the microwave oven heating technique, which
showed to be effective for the retrieval of masked epi-
topes of many antigens. The primary antibodies used were
mouse monoclonal antibodies (clone DO-7) recognizing a
denaturation-resistant epitope between amino acids 35 and
45 and have been shown to recognize both the wild-type
and mutant forms of p53 protein [18]. Briefly, after dewaxing,
endogenous peroxidase activity was blocked by incubating
the sections withmethanol containing 3% hydrogen peroxide
for 20min. After preincubation with normal rabbit serum
(diluted 1 : 5) for 20min, a three-step immunoperoxidase
procedure was applied: first, with the primary antibodies
DO-7 at the appropriate working dilution 1 : 50 in 0.1% BSA
overnight at 4∘C, second, with biotinylated rabbit anti-mouse
immunoglobulin (diluted 1 : 250 in 0.1% BSA) for one hour at
room temperature, and third, with strept ABComplex-HRP
(diluted 1 : 100) for 40min. Finally, the sections were visual-
ized by incubation with diaminobenzidine tetrahydrochlo-
ride (DAB) in hydrogen peroxide substrate with 50mg of
imidazole for 10min. The sections were counterstained with
methyl green (0.5%, 2min) or Harris haematoxylin to visual-
ize nuclei.We also used the alkaline phosphatase anti-alkaline
phosphatase (APAAP) immunohistochemical technique [19].
Negative control slides were processed with each slide run
and excluded the primary antibody but included all other
steps of the procedure. A human breast carcinoma cell line,
which expresses p53 suppressor gene product, is used as the
positive control. The IHC staining was semiquantitatively
scored by 2 of the authors. We studied the tissue samples by
assessing the site of staining, the proportion of cell staining
(counting at least 1000 cells/sample), and the intensity of
staining: weak (1+), moderate (2+), or strong (3+). Scoring
was as follows: 1%–10% tumor cell nuclei staining for p53 =
1+; 11%–30% tumor cell nuclei staining for p53 = 2+; 31%–
50% tumor cell nuclei staining for p53 = 3+; >50% tumor cell
nuclei staining for p53 = 4+.
2.6. Statistical Analysis. The significance of differences
between different experimental values was assessed bymeans
of ANOVA and Student’s 𝑡-test. Data were tested at a statis-
tical significance level of 𝑃 < 0.05 and expressed as mean ±
SEM. All statistical manipulations were performed using the
SPSS for Windows software system.
3. Results
3.1. Expression of p53 Protein in Breast Carcinoma: Immuno-
histochemistry and Western Blot Analysis. A distinct nuclear
and cytoplasmic immunoreaction for p53 was judged as
positive. Thirty of the 47 cases showed a positive immunore-
action with DO-7. Positive cells were distributed evenly in
the cancerous tissue and there were 18 cases of 10–30% of
positivity in tumor cells, 9 of 30–50%, and 3 of more than
50% in the 30 positive cases. In the positive cells the nuclear
staining patterns were strong or diffuse (Figures 2 and 3).
A similar localization is obtained with alkaline phosphatase-
fast red detection (Figure 4). In contrast to the darker, more
sharply defined nuclear staining, a diffuse pattern of staining
was identified in the cytoplasm of tumor cells (Figure 3).
Cytologic samples of nonmalignant lesions were always
negative (Figure 1(a)). There was a strong association among
nuclear p53 immunoreaction and histologic grade of breast
cancer: 66% of grade 3 cases, 34% of grade 2 cases, and none
(0%) of grade 1 cases. In the first series, the nuclear p53
immunoreaction was positive in three of four patients who
died of breast cancer, whereas only one of 23 patients died
among the negative cases. There was a significant difference
in the overall survival between the group with a positive
p53 immunoreaction detected by DO-7 and the other group
with no p53 immunoreaction. In Serbian patients, we were
able to confirm that nuclear p53 immunoreaction was more
frequent in aggressive breast cancers, for example, those with
histologic grade 3 and advanced clinical stage (Figure 1(b)).
In fact, breast carcinomas that progress to the invasive stage
tend to be more frequently p53-positive. It was also shown
that a high pathological grade is statistically significantly
associated with increased expression of p53 (𝑃 < 0.01,
𝑡-test). This may have diagnostic relevance because strong
and diffuse p53 immunoreactivity has never been described
in nonneoplastic breast tissues. Interestingly, we observed
a greater nuclear staining for p53 protein at the invasive
margins of the tumors. Tumor cell nuclei at the invasive
front frequently displayed an elongated elliptical shape and
had deeply invaginated surfaces (Figure 3). Smaller tumor
cell nuclei showed ball-like shape (Figure 5). This result
therefore is only one more indicator of the heterogeneity of
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Figure 1: p53 immunohistochemical staining in normal breast tissue
and breast cancer. (a) No p53 immunoreactivity was observed in
the normal breast cells. (b) A mutant case with strongly posi-
tive nuclear staining. Positive p53 immunoreaction in the tumor
area is indicated by brown color. Negative nuclei show only the
counterstain, indicated by the blue color. Immunostaining was
performed with the mouse anti-human p53 monoclonal antibody
DO-7. (Immunoperoxidase staining with nuclear counterstain with
hematoxylin. Magnification: ×63.)
malignant breast epithelial cells. The high resolution of the
light microscopy provides a relatively precise detection of
deep and narrow invaginations of nuclearmembrane and also
points to differences in the surface structure of the nuclei.
Our data also suggested that immunohistochemistry for p53
proteinwould be clinically useful for predicting the prognosis
of patients. Nuclear p53 immunoreaction was frequently
detected in histologic grade 3 breast cancers, which have a
poor prognosis. A high histologic grade of breast cancer is
determined by the presence of structural and nuclear atypia
and an increased number of mitotic figures in cancer cells.
Therefore, alterations in p53 gene and overexpression of p53
protein are suggested to be involved in loss of differentiation,
formation of nuclear polymorphism and a coarse chromatin
pattern, and/or rapid growth of breast cancer.
One of the most intriguing findings is that mutant and/or
wild-type p53 appear as discrete dot-shaped regions within
the nucleus of breast carcinoma cells (Figure 5). In many
malignant cells the nucleolar sequestration of p53 is evident
(Figure 5).
When the CM-1 antibody that had been generated against
full-length p53 (recognized 1–393 aa, in wild-type andmutant
p53 protein forms) was used in our study p53, p53𝛽 (48 kDa),
ΔNp53 (47 kDa), and Δ133p53𝛽 (35 kDa) were detected in
breast carcinomas (Figure 6).The authors found thatmultiple
bands ranging from 24 to 53 kDa were detected in p53-
expressing but not in p53-nonexpressing cells (Figure 6) sup-
porting the notion that multiple p53 isoforms are expressed
in breast cancer cells. Western blot analysis of the nuclear
fraction of breast cancer cells revealed theΔ133p53𝛽 (35 kDa)
isoform to be the dominant form in the invasive breast
carcinomas (Figure 6, lines 4, 5, and 7) compared to non-
invasive cases (lines 3 and 6). Importantly, none of the
tumors had the same p53 isoform expression pattern. The
Figure 2: p53 immunostaining in malignant cells from an invasive
(ductal) breast carcinoma. Immunoreactivity specific for p53 was
detected in the tumor cell nuclei. Perinuclear p53 immunolocal-
ization is evident. Tumor cell nuclei were more frequently ball-like
shaped or displayed an elliptic shape. Sequestered p53 localizes to
large aggregates in the cytoplasm (avidin-biotin immunoperoxidase
technique with mAb DO-7, counterstained with methyl green,
×320).
Figure 3: p53 immunoreactivity in infiltrating ductal carcinoma
of the breast (invasive margins). Anti-p53 cell staining showing
variation in the distribution and intensity of staining. In contrast to
the darker, more sharply defined nuclear staining, a diffuse pattern
of staining was identified in the cytoplasm of tumor cells. Larger
and more irregular tumor cell nuclei had deeply invaginated sur-
faces (frozen section, immunoperoxidase with mAb DO-7, nuclear
counterstain with haematoxylin, ×320).
isoforms expressed also varied between individual tumors,
indicating potential roles of these p53 variants in human
breast cancer. In fact, expression of multiple p53 isoforms
varied between phenotypically distinct subset of cases. The
presence ofΔ133p53𝛽 (35 kDa) andΔNp53 (47 kDa) isoforms
is of critical importance in breast cancers with a wild-type
p53.
We confirm the previously described variants in breast
cancer tissues (p53𝛽, ΔNp53, and Δ133p53𝛽) and novel
isoforms (49, 45, 36, 34, 29, 28, and 24 kDa), thereby, fur-
ther enlarging combinatorial possibilities. Our experiments
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Figure 4: p53 immunostaining in malignant breast epithelial cells.
Almost all neoplastic cell nuclei reveal strong accumulation of
the p53 protein. p53-positive cells have red nuclei and a green
staining underlines nuclei of unlabelled cells (frozen section, alka-
line phosphatase antialkaline phosphatase—APAAP—technique,
monoclonal antibody Pab240, fast red chromogen, counterstained
with methyl green, ×250).
Figure 5: Unusual expression and cell compartmentalization of
p53 protein in breast carcinoma cells. By immunohistochemical
staining, p53 appears as discrete dot-shaped regions within the
nucleus of the cell. p53 cancer-associatedmutants localize to distinct
domains in the nucleoli and at and around the nuclear membrane.
The antibody reacted with a distinct perinuclear structure in almost
all of the cells. Cytoplasmic p53 was observed as faint staining.
Smaller tumor cell nuclei showed ball-like shape (frozen section,
immunoperoxidase with antibody DO-7, nuclear counterstain with
haematoxylin, ×250).
cannot determine whether the identified p53 isoforms asso-
ciate with p53 individually or as part of a multicomponent
complex. The protein level of each band was quantified by
transmission scanning and analyzed by Gel-Pro Analyzer 3.1
(Figure 6(b)).
4. Discussion
In this study we used a panel of anti-p53 antibodies (DO-7,
CM-1, and PAb240) for cell staining and found abnormalities
in at least 30% of cases. DO-7 has shown to be one of themost
sensitive for the detection of p53 overexpression [18]. Other
literature data also support that rabbit p53 antibody CM-1 is
highly sensitive for the p53 staining [11]. In addition, the CM-
1 antibody is polyclonal and theoretically should recognize all
forms of p53. It is widely accepted that, in normal tissues,
p53 protein is present in such low quantities that it is not
readily detectable by immunochemical techniques. Thus, the
accumulation of p53 protein in normal breast epithelial cells
is a highly unusual finding because the abnormally stabilized
p53 protein has only been associated with malignant disease
and DNA damage. Moreover, the half-life of p53 is extended
from several minutes to several hours which is thought to be
characteristic of a transformed phenotype.
The monoclonal PAb240 antibody reliably detects a wide
variety of p53mutations and thesemutations have a common
effect on the structure of p53. An antibody PAb240 does not
immunoprecipitate wild-type p53.
Extensive evidence has shown thatmutation or functional
inactivation of the tumor suppressor p53 is an almost uni-
versal feature of human cancer. Previous studies suggest that
mutant-type p53 has an influence on the prognosis of patients
in many cancers including breast carcinoma and is associ-
ated with tumor staging, multidrug resistance, response to
chemotherapy or radiotherapy, postsurgery recurrence, and
metastasis [4, 6, 20]. Further analyses of point and truncated
mutant expression products of the p53 gene have shown that
mutant p53 proteins not only lose their tumor suppressive
functions but may also gain new abilities that enhance
tumorigenesis [21–25]. These data implicate transcriptional
activation by mutant p53 as a key mechanism responsible for
its oncogenic activity. Indeed, the p53mutation is linked with
chemoresistance and transformation to a more aggressive
disease in many tumor types [26]. In the present study, we
found that the higher expression levels of mutant p53 protein
in most breast cancers analyzed were associated with more
frequent lymph node metastasis, advanced TNM stage, and
poor survival which is consistent with other reports [6, 27].
The role of TP53 mutation as a prognostic marker is
reviewed as well as its role as a predictor for therapy response.
All data available on TP53mutation analyses of human breast
carcinomas support an important role for TP53 in mammary
carcinogenesis [27, 28]. The use of different antibodies,
staining standards, tumor material, scores for positivity, and
the inclusion of variously selected groups of breast cancer
patients might be the reason why the frequency of positive
p53 staining ranges from 20 to 60% in the literature [29–
31]. The rate of positive IHC was as high as 64% in our
study and 36% cases had a complete lack of detectable
staining. The nondetectable levels of p53 in the p53-negative
tumors are either the very low wild-type levels or due to
loss of p53 (deletion mutants) the overexpression of mdm2
and mdm2-mediated p53 degradation. This is in perfect
agreement with the results described earlier [27]. Hence,
excluding technical reasons, we tend to attribute the high
rate of positive p53 staining in our study to the selection
of patients with advanced stages of breast cancer (T3 and
T4 tumors). We also hypothesized that expression profiling
of p53 in breast cancer would lead to the identification of
a molecular signature that can predict metastatic potential.
Generally, the nuclear p53 immunoreaction was considered
to reflect nuclear accumulation of mutant p53 protein which


















































Figure 6: (a)Western blot analysis of p53 expressed in the nuclear fraction of human breast cancer cells revealed a wide spectrum of isoforms
(49, 48, 47, 45, 36, 35, 34, 29, 28, and 24 kDa). These isoforms were not present in nontransformed cells (control cases, lines 1 and 2). Only
the Δ133p53𝛽 (35 kDa) and ∼36 kDa isoforms are present at higher levels in the invasive breast carcinomas (lines 4, 5, and 7) compared
to noninvasive cases (lines 3 and 6). The analysis suggested coexpression of mutant forms of p53 and/or wild-type p53 with p53 isoforms
indicated. Expression of multiple p53 isoforms varied between phenotypically distinct subset of cases. In normal breast tissues, expression of
p53 is either very low or not measurable. Equal amounts of nuclear proteins (50𝜇g/lane) from extracts of normal and breast cancer tissues
were separated on 12% SDS-PAGE and transferred to nitrocellulose membrane. Incubation with CM-1 rabbit polyclonal antibody (diluted
1 : 1000) was followed by incubation with biotinylated swine anti-rabbit Ig serum (diluted 1 : 1000) and strept ABComplex-HRP conjugated as
described in Section 2. HRP was detected with DAB as chromogen. Bottom panel shows actin loading control. All Western immunoblotting
experiments were performed at least twice with similar results. Lines 1 and 2—normal breast tissue. Lines 4, 5, and 7—invasive ductal breast
carcinomas. Lines 3 and 6—noninvasive breast carcinomas. Molecular mass markers are presented on the left (MW).The position of the p53
is indicated by the arrow. The arrows denote the position of the p53 isoforms. (b) Relative abundance of p53 and its isoforms in the nuclear
fraction of breast cancer cells. The levels of p53 and its isoforms in each sample were quantified using transmission scanning and analyzed by
Gel-Pro Analyzer 3.1. Significant increase of the p53 and its isoforms (35 and 36 kDa) is evident in nuclear fraction of breast cancer cells.
is coded by the mutated form of the p53 gene, and has a
prolonged half-life. From these findings and our present ones
(Figures 2, 3, and 4), it is suggested that breast cancer showing
a positive nuclear p53 immunoreaction carries the mutated
p53 gene and thatmutation of p53may play an important role
as a mechanism for aggressive biological behavior of human
breast cancer. Since p53 mutations could reflect a higher
rate of proliferation and more advanced state of progression
[24], breast tumors with these p53 alterations, as evidenced
by nuclear accumulation of protein, could have a greater
probability of having micrometastasis and thus a greater
probability of recurrence [27]. Olivier et al. [27] hypothesize
that p53 mutations (mp p53) are associated with decreased
expression of thrombospondin 1 (TSP-1) and that decreased
TSP-1 expression is associated with lymph node metastases.
Subsequent analyses of large series of individual tumor types
have, however, revealed a much more complex story [32–35].
Thepossibility that p53 status influences biological behav-
ior was raised in an early study in which the presence of
p53 mutations in aggressive breast cancer was demonstrated
[36] and the majority of studies support the existence of an
association between worse survival and the presence of p53
mutations. This association was confirmed in a comprehen-
sive meta-analysis of the effect of somatic p53 mutations on
prognosis in breast cancer [37]. However, the difficulty to link
p53mutation status to clinical outcome and cancer treatment
can be explained by the fact that mutations of the p53 gene
do not necessarily result in inactivation of p53 transcriptional
activity [20]. Hence, 60% of the mutations that can occur
in the p53 gene do not alter p53 transcriptional activity.
Only 15% of the mutations lead to mutant p53 completely
inactive in transactivation. In the remaining 25% mutants,
p53 presents differential transcriptional activity. They can
transactivate some promoters but are completely inactive on
others. It is therefore important to establish whether p53
mutation is correlated with loss of p53 function to determine
accurately p53 status in clinical studies.
A large number of studies have assessed the prognostic
and predictive role of TP53 alterations in breast cancer yield-
ing conflicting results. Two different methodologies have
been used to assess TP53 alterations: DNA sequencing and
immunohistochemistry (IHC). Most TP53 alteration found
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in breast carcinomas are point mutations leading to the syn-
thesis of a stable, malfunctional, and nondegradable protein
that accumulates in tumor cells and thus can be detected
by IHC. The correlation between p53 protein accumulation
measured by IHC andTP53mutation detected by sequencing
is, however, less than 75% in breast carcinomas [38]. The
reason for this is that not all mutations yield a stable protein
and somemutations result in protein truncation and are thus
not detected by IHC. Studies that have used sequencing to
detect mutations all showed a strong association to survival,
whereas most studies using IHC failed to detect such an
association [39]. Careful studies of microdissected tumor
material have shown that TP53 mutations can occur in
ductal carcinoma in situ (DCIS) before the development
of invasive breast cancer, and that the frequency increases
from around 0% in low-grade DCIS to 30–40% in high-
grade DCIS [40–42].These results point to an important role
of TP53 alterations early in the carcinogenic process of the
breast. The frequency of TP53 mutations reported in breast
tumors ranges from 15 to 71% [43]. Significant differences are
seen among populations, although the different distribution
of various stages, as well as whether the whole gene was
screened or only the conserved region from exons 5–8, may
have influenced the frequency found in the various studies.
The frequencies in node-negative patients are on the whole
considerably lower (15–18%) than in node-positive patients
and large tumors from patients with advanced disease have
a higher frequency of mutations than small tumors [44].
An increased frequency during tumor progression has also
been observed [4, 45]. Analysis of the p53mutation spectrum
[46, 47] indicates that ∼5–15% of the p53 mutations occur in
the C-terminal domain (CTD) during human tumorigenesis.
Most of the somatic mutations in the p53 CTD are either
nonsense mutations or lead to frameshifts, resulting in a
truncated protein. The results have revealed that all mutants
have impaired apoptotic activity when compared with wild-
type p53 [48]. These and other data indicate that CTD of
p53 is an important component of p53-mediated apoptosis
and cell growth arrest and that inactivation of the apoptotic
function, but not the inhibition of growth, is an important
step during human tumorigenesis [48].
In many malignant cells, the nucleolar sequestration of
p53 is evident (Figure 5). These observations suggest a link
between p53 breast cancer-associatedmutants and ribosomal
biogenesis. The nucleolus is the major site of ribosome bio-
genesis andwe now show thatmutant and/or wild-type forms
of p53 associate with nucleolar structures (Figure 5). The
subpopulation of nucleolar p53may be involved in ribosomal
processing. Nucleolar transcription is considered to occur in
the transition zone between the fibrillar centres and the dense
fibrillar component, whilst rRNA processing progresses from
the dense fibrillar component to the granular component
[49]. Our results are in agreement with a similar observation
reported in the literature that high intensity fibrillarin spots
reveal the dense fibrillar component [49]. Interestingly, we
observed nucleolar p53 spots both in high and low fibrillarin
regions (Figure 5), thus supporting the idea that mutant
and/or wild-type forms of p53 might be associated with
several nucleolar functions. It is likely that the answer lies
within the realm of the nucleolus, which is the central factory
for ribosome biosynthesis and assembly and where the key
regulators of p53 (Arf, mdm2, L5/L11/L23, and p53 itself)
reside at some point [50, 51]. p53 mutants specifically bind
to nuclear matrix attachment region (MAR) DNA elements.
MAR elements constitute important higher-order regulatory
elements of chromatin structure and function. By binding to
these elements, mutant forms of p53 could modulate impor-
tant cellular processes, like gene expression, replication, and
recombination, resulting in phenotypic alterations of the
tumor cells [52–55].
Although the interpatient variability was large, we found
that tumor cell nuclei at the invasive front frequently dis-
played an elliptic shape and had deeply invaginated surfaces
(Figure 3). In contrast, the majority of the tumor cell nuclei
analyzed were ball-shaped (Figures 2 and 5). It is therefore
possible that the nuclear surface and area are reliable markers
for terminal stages of the biochemical differentiation of
breast carcinoma. It is noteworthy that regulation of cell
differentiation is most often impaired in malignant tumors
and may represent a key mechanism for the progression
of the disease. It should be remembered, however, that the
disruption of normal epithelial differentiation represents a
primary event in the initiation of a malignant phenotype.
Indeed, a switch in differentiation state can play a major
causal role in tumor evolution by altering the selection
pressure for p53 mutation [56].
In keeping with its function as a transcription factor, p53
is predominately a nuclear protein. However, a fraction of p53
can be found in the cytoplasm, suggesting a transcriptionally
independent function for this pool of p53. The binding of
the various forms of p53 to plasma membranes (Figures 3
and 5) suggests that a subset of membrane proteins and
a variety of molecules including phospholipids and pro-
teoglycans have binding sites for these structurally distinct
forms of p53. Membrane lipid domains have been proposed
to be involved in a variety of different functions including
signal transduction, lipid transport and metabolism, and cell
growth. Thus, the various effects of p53 binding to these
membrane molecules suggest other roles of p53 than at the
transcriptome level. Binding of p53 to the membrane could
also have consequence on p53 itself. p53 signaling, there-
fore, appears “soft-wired”, modular, and highly flexible with
substantial overlap between different response pathways.The
cellular background likely profoundly affects the nature of the
response.
To investigate whether expression of various p53 isoforms
might be responsible for clinical observations, thirty ran-
domly selected breast tumors were analyzed for expression
profiles of different p53 isoforms, by Western blot anal-
ysis (Figure 5). Whereas normal human breast does not
express any of the corresponding isoforms, different p53
isoforms are detected in the majority of breast tumors at
apparently different levels (Figure 5). This is most probably
true and such hypothesis is consistent with experimental
evidence showing abnormal expression of p53 isoforms in
breast tumors [57]: p53𝛽, which lacks the carboxy-terminal
oligomerization domain due to alternative mRNA splicing;
Δ133p53, which lacks the amino-terminal transactivation
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and proline-rich domains due to the transcription from an
alternative promoter in intron 4; Δ40p53, also named p47
or ΔNp53, as an amino-terminally truncated p53 isoform
deleted from the first 40 amino acids. ΔNp53 protein can be
generated either by an alternative splicing of the intron 2 or
by alternative initiation of translation [57] and can act in a
dominant-negative manner towards wild-type p53 inhibiting
both p53 transcriptional activity and p53-mediated apoptosis
[58]. Therefore, the human p53 gene can encode at least nine
different p53 protein isoforms [57]. ΔNp53 contains a shorter
N-terminus (lacking 39 aa) and Δ133p53 lacks the whole N-
terminal region plus part of the DNA-binding domain [59].
Rohaly et al. [60] attempt to demonstrate endogenous
Δp53 expression using a panel of p53 monoclonal antibodies.
The authors could detect a p53 band at 45 kDa with DO-
1, which was interpreted as proving the expression of the
Δp53 isoform. However, this should be interpreted with
caution, as Bourdon et al. [57] showed that p53𝛽, p53𝛾, and
Δ40p53 migrate all at 45 kDa. Therefore, the 45 kDa band
identified by Rohaly et al. [60] is probably composed of a
mix of Δp53, p53𝛽, p53𝛾, and Δ40p53. Δp53, which lacks
a conserved domain of p53 in the DNA-binding domain,
was reported to be transcriptionally active towards some
p53 target genes and to be critical for the intra-S phase
checkpoint [60]. Contrary to previous publications, Wan and
Poon [61] reported with strong experimental evidences that
Δp53 isoform lacks intrinsic transcriptional activity and lacks
dominant-negative activity towards full-length p53. This is
probably because Δp53 is not imported into the nucleus
and stays in the cytoplasm. Therefore, further studies will
be required to establish expression of the endogenous Δp53
isoforms and its biological relevance. By using the CM-
1 antibody (which detects p53, p53𝛽, and Δ133p53), Fujita
et al. [62] showed that p53𝛽 and Δ133p53 were expressed
less abundantly than full-length p53 but were still at readily
detectable levels in human fibroblast strains MRC-5 andWI-
38. Bourdon et al. [63] have reported an analysis of expression
of p53𝛽 and p53𝛾 in relation to clinical and pathological
markers and disease outcome in a cohort of 127 randomly
selected primary breast tumors. p53𝛽 was associated with
tumor estrogen receptor (ER) expression, and p53𝛾 was
associated with mutation of the p53 gene. The patients group
with the mutant p53 breast tumor-expressing p53𝛾 isoform
had low cancer recurrence and an overall survival as good as
that of patients with wild-type p53 breast cancer Conversely,
patients expressing only mutant p53, without p53𝛾 isoform
expression, had a particularly poor prognosis.
When theCM-1 antibody, that had been generated against
full-length p53, was used in our study, p53, p53𝛽 (48 kDa),
ΔNp53 (47 kDa), and Δ133p53 (35 kDa) were detected in
breast carcinomas (Figure 6).This analysis demonstrated that
the CM-1 antibody is specific for the unique epitope at the
ΔNp53 and 𝛽 isoform subclasses, p53𝛽 and Δ133p53𝛽. It
was published that the 133p53 isoform is a direct p53 target
gene that modulates p53 tumour suppressor activity [57].
Since the majority of the tumors analyzed had an abnormal
pattern of p53 isoform compared to that of normal breast
tissue, the authors speculate that an imbalance in isoform
expression may thwart p53’s tumor suppressive capabilities,
thereby accelerating the tumorigenic process in the absence
of p53 mutation. It is noteworthy that the dominant-negative
effect of N-terminally truncated isoforms on the activity of
full-length isoforms has been demonstrated [57]. Indeed,
Bourdon et al. [57] found that tumors that retain wild-type
p53 often express an abnormal balance of p53 isoforms.
Since N-terminally truncated p53 isoforms can regulate p53
activity, an alteration in the ratio of different p53 isoforms
may predispose to cancer and might even explain the lack
of correlation between p53 mutational status and response
to anticancer therapies. Whereas only 25% of breast tumors
express mutant p53, p53𝛽, and p53𝛾, expressions are fre-
quently lost (60%) and Δ133p53 is frequently overexpressed
in breast tumors [57].
Themost parsimonial explanation of the results described
above is that p53 mutation (or the associated elevation of cel-
lular p53 protein levels) is the commonest genetic alteration
detected in primary breast carcinoma cells. Overexpression
of p53 in primary breast cancer is associated with high tumor
grade and nodal metastases. It should be pointed out that
there is also an increase in the level of p53 isoforms in
the majority of the invasive breast carcinomas studied in
detail. It is possible that the dominant-negative ΔN forms of
p53 were generally detected in these tumor cells so a role
in the regulation of p53 function has been hypothesized.
The discovery that ΔNp53 is the dominant isotype in breast
carcinoma does suggest a plausible mechanism by which the
p53 present in these tumors is prevented from functioning as
a transactivator. If the two proteins, dominant-negative vari-
ants that lack the amino-terminal transactivation domain,
compete for binding sites on DNA,ΔNp53 andΔ133p53𝛽will
very effectively act as a dominant-negative repressor of p53
function. Based on our experience, structured and funded
qualitative research is required to establish why such high
levels of p53 isoforms exist in invasive breast carcinoma cells.
These cells should also serve in clarification of the process
leading to transformation by mutant forms of p53. The most
straightforward conclusion is that many questions remain
to be answered about the tumor derived p53 mutants and
the intricate network involving members of the p53 family.
Further work in this area should help provide a new insight
into the mode of action of mutant forms of p53 and p53
isoforms in breast carcinoma cells as well as their potential
clinical relevance.
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